uniQure NV
Suletud
26.7 -4.91
Ülevaade
Aktsiahinna muutus
24h
Min
26.23
Max
28.08
Sissetulek | -16M -54M |
|---|---|
Müük | -2M 3.6M |
Aktsiakasum | -0.73 |
Kasumimarginaal | -1,502.948 |
Töötajad | 221 |
EBITDA | 13M -36M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +49.22% upside |
Järgmine tulemuste avaldamine | 28. juuli 2026 |
|---|
Turukapital | 476M 1.8B |
|---|---|
Eelmine avamishind | 31.61 |
Eelmine sulgemishind | 26.7 |
uniQure NV Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
uniQure NV Prognoos
Hinnasiht
By TipRanks
49.22% tõus
12 kuu keskmine prognoos
Keskmine 42.11 USD 49.22%
Kõrge 95 USD
Madal 14 USD
Põhineb 10 Wall Streeti analüütiku instrumendi uniQure NV 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
